search
Back to results

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Saxagliptin
Metformin XR
Placebo matching Metformin XR
Metformin XR
Placebo matching Saxagliptin
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

18 Years - 78 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 diabetes
  • 18-78 years of age
  • Taking stable dose of metformin immediate release (IR) or XR ≥850 mg and ≤1500 mg as monotherapy for at least 8 weeks prior to screening
  • Glycosylated hemoglobin A1C (A1C) 7.5-11.5% at screening
  • Fasting C-peptide: ≥1.0 ng/mL
  • FPG≥126 mg/dl obtained at the Day -7 visit
  • Body mass index (BMI): ≤ 40kg/m²
  • A1C ≥ 7.0% and ≤ 11.0% obtained at the Day -7 visit for randomization

Exclusion Criteria:

  • Women of childbearing potential unable or unwilling to use acceptable birth control
  • Women who are pregnant or breastfeeding
  • Significant cardiovascular history
  • Active liver disease
  • Renal impairment

Sites / Locations

  • Dedicated Phase I, Inc.
  • Pacific Sleep Medicine Services (Avastra Clinical Trials)
  • Orange County Research Center
  • Clinical Research Of South Florida
  • Palm Springs Research Institute
  • Healthcare Clinical Data, Inc.
  • River Birch Research Alliance, Llc
  • Jasper Clinic, Inc.
  • Clinilabs, Inc.
  • Medpace Clinical Pharmacology Unit
  • Clinical Trials Of Texas Inc.
  • Advanced Clinical Research
  • Local Institution
  • Local Institution
  • Local Institution
  • Local Institution
  • Local Institution
  • Local Institution
  • Local Institution
  • Local Institution
  • Local Institution

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Saxagliptin + Metformin XR + matching Metformin XR placebo

Metformin XR + Metformin XR + matching Saxagliptin placebo

Arm Description

(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)

(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)

Outcomes

Primary Outcome Measures

Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4
Adjusted mean change from baseline in MWG achieved with saxagliptin 5 mg plus metformin XR versus placebo plus metformin XR at Week 24. MWG was calculated as the area under the curve (AUC) for the full 24 hours expressed as average mg/dL. Glucose measurements were collected 30 minutes before and just prior to each meal (0 minutes) and 30, 60, 120, and 180 minutes after each meal (with 1 additional measurement at 240 minutes after the evening meal), midnight, 3 AM, and at end-of-domicile visit 24 hours after the first measurement. Mean change from baseline was adjusted for baseline value.

Secondary Outcome Measures

Change From Baseline to Week 4 in 2-hour Postprandial Glucose (PPG) (2 Hours After the Evening Meal)
Adjusted mean change from baseline in 2-hour postprandial (after mealtime) plasma glucose two hours after start of the evening meal during 24-hour domicile visits evaluated both at pre-randomization (baseline) and at Week 4. Mean change from baseline was adjusted for baseline value.
Change From Baseline Fasting Plasma Glucose (FPG) at Week 4, Obtained Immediately Before the Morning Meal
FPG measurements were done at baseline, day 14 and 28. At baseline and day 28, the FPG value=plasma glucose value collected 30 minutes prior to the morning meal during the domicile visit.

Full Information

First Posted
June 9, 2009
Last Updated
May 4, 2015
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT00918138
Brief Title
Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg
Official Title
A 4-Week, Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy of Saxagliptin in Combination With Metformin XR 1500 mg Versus Up-titrated Metformin XR to 2000 mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise and a Stable Dose of Metformin XR 1500 mg
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
August 2009 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
May 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study was to compare effect of Saxagliptin as add-on to Metformin on 24-hour mean weighted glucose (MWG) to the effect of uptitrating Metformin in subjects with T2DM inadequately controlled on metformin alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
219 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Saxagliptin + Metformin XR + matching Metformin XR placebo
Arm Type
Experimental
Arm Description
(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)
Arm Title
Metformin XR + Metformin XR + matching Saxagliptin placebo
Arm Type
Active Comparator
Arm Description
(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)
Intervention Type
Drug
Intervention Name(s)
Saxagliptin
Other Intervention Name(s)
BMS-477118, Onglyza
Intervention Description
Tablets, Oral, 5 mg, once daily, 4 weeks
Intervention Type
Drug
Intervention Name(s)
Metformin XR
Other Intervention Name(s)
Glucophage XR®
Intervention Description
Tablets, Oral, 1500 mg, once daily, 4 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo matching Metformin XR
Intervention Description
Tablets, Oral, 0 mg, once daily, 4 weeks
Intervention Type
Drug
Intervention Name(s)
Metformin XR
Other Intervention Name(s)
Glucophage XR®
Intervention Description
Tablets, Oral, 500 mg, once daily, 4 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo matching Saxagliptin
Intervention Description
Tablets, Oral, 0 mg, once daily, 4 weeks
Primary Outcome Measure Information:
Title
Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4
Description
Adjusted mean change from baseline in MWG achieved with saxagliptin 5 mg plus metformin XR versus placebo plus metformin XR at Week 24. MWG was calculated as the area under the curve (AUC) for the full 24 hours expressed as average mg/dL. Glucose measurements were collected 30 minutes before and just prior to each meal (0 minutes) and 30, 60, 120, and 180 minutes after each meal (with 1 additional measurement at 240 minutes after the evening meal), midnight, 3 AM, and at end-of-domicile visit 24 hours after the first measurement. Mean change from baseline was adjusted for baseline value.
Time Frame
Baseline, Week 4
Secondary Outcome Measure Information:
Title
Change From Baseline to Week 4 in 2-hour Postprandial Glucose (PPG) (2 Hours After the Evening Meal)
Description
Adjusted mean change from baseline in 2-hour postprandial (after mealtime) plasma glucose two hours after start of the evening meal during 24-hour domicile visits evaluated both at pre-randomization (baseline) and at Week 4. Mean change from baseline was adjusted for baseline value.
Time Frame
Baseline, Week 4
Title
Change From Baseline Fasting Plasma Glucose (FPG) at Week 4, Obtained Immediately Before the Morning Meal
Description
FPG measurements were done at baseline, day 14 and 28. At baseline and day 28, the FPG value=plasma glucose value collected 30 minutes prior to the morning meal during the domicile visit.
Time Frame
Baseline, Week 4
Other Pre-specified Outcome Measures:
Title
Participants With Confirmed Hypoglycemia Events During the Treatment Period
Description
'Confirmed' = recorded on the hypoglycemia AE case report form with a fingerstick for glucose <= 50 mg/dL and associated symptoms.
Time Frame
AEs: up to last treatment day (LTD) +1 day or last visit day (LVD), whichever came last ; SAEs: up to LTD +30 days or LVD + 30 days, whichever came last. Mean duration of exposure=27.7 days for Saxa 5 mg + Met XR 1500 mg, and 28.3 days for Met 2000 mg.
Title
Participants With Reported Hypoglycemic Adverse Events During Treatment Period
Description
Hypoglycemic events are based upon the Saxagliptin Predefined List of Events, which includes hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness. The Hypoglycemic events occurred in less than 5% of the participants and hence do not appear in the adverse events module.
Time Frame
AEs: up to last treatment day (LTD) +1 day or last visit day (LVD), whichever came last ; SAEs: up to LTD +30 days or LVD + 30 days, whichever came last. Mean duration of exposure=27.7 days for Saxa 5 mg + Met XR 1500 mg, and 28.3 days for Met 2000 mg.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
78 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes 18-78 years of age Taking stable dose of metformin immediate release (IR) or XR ≥850 mg and ≤1500 mg as monotherapy for at least 8 weeks prior to screening Glycosylated hemoglobin A1C (A1C) 7.5-11.5% at screening Fasting C-peptide: ≥1.0 ng/mL FPG≥126 mg/dl obtained at the Day -7 visit Body mass index (BMI): ≤ 40kg/m² A1C ≥ 7.0% and ≤ 11.0% obtained at the Day -7 visit for randomization Exclusion Criteria: Women of childbearing potential unable or unwilling to use acceptable birth control Women who are pregnant or breastfeeding Significant cardiovascular history Active liver disease Renal impairment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Dedicated Phase I, Inc.
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
Facility Name
Pacific Sleep Medicine Services (Avastra Clinical Trials)
City
Redlands
State/Province
California
ZIP/Postal Code
92373
Country
United States
Facility Name
Orange County Research Center
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
Facility Name
Clinical Research Of South Florida
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Facility Name
Palm Springs Research Institute
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33012
Country
United States
Facility Name
Healthcare Clinical Data, Inc.
City
North Miami
State/Province
Florida
ZIP/Postal Code
33161
Country
United States
Facility Name
River Birch Research Alliance, Llc
City
Blue Ridge
State/Province
Georgia
ZIP/Postal Code
30513
Country
United States
Facility Name
Jasper Clinic, Inc.
City
Kalamazoo
State/Province
Michigan
ZIP/Postal Code
49007
Country
United States
Facility Name
Clinilabs, Inc.
City
New York
State/Province
New York
ZIP/Postal Code
10019
Country
United States
Facility Name
Medpace Clinical Pharmacology Unit
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45212
Country
United States
Facility Name
Clinical Trials Of Texas Inc.
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Advanced Clinical Research
City
West Jordan
State/Province
Utah
ZIP/Postal Code
84088
Country
United States
Facility Name
Local Institution
City
Capital Federal
State/Province
Buenos Aires
ZIP/Postal Code
1429
Country
Argentina
Facility Name
Local Institution
City
Buenos Aires
ZIP/Postal Code
1425
Country
Argentina
Facility Name
Local Institution
City
Beer-Sheva
ZIP/Postal Code
84101
Country
Israel
Facility Name
Local Institution
City
Holon
ZIP/Postal Code
58100
Country
Israel
Facility Name
Local Institution
City
Kfar-Saba
ZIP/Postal Code
44281
Country
Israel
Facility Name
Local Institution
City
Zefat
ZIP/Postal Code
13100
Country
Israel
Facility Name
Local Institution
City
Monterrey
State/Province
Nuevo Leon
ZIP/Postal Code
64460
Country
Mexico
Facility Name
Local Institution
City
Durango
ZIP/Postal Code
34000
Country
Mexico
Facility Name
Local Institution
City
Durango
ZIP/Postal Code
34075
Country
Mexico

12. IPD Sharing Statement

Learn more about this trial

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

We'll reach out to this number within 24 hrs